Pharmacodynamic Target Evaluation of a Novel Oral Glucan Synthase Inhibitor, SCY-078 (MK-3118), Using anIn VivoMurine Invasive Candidiasis Model

Isavuconazole Pharmacodynamic Target Determination for Candida Species in anIn VivoMurine Disseminated Candidiasis Model

(2013) Alexander J. Lepak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations

(2013) Barbara D. Alexander et al.   CLINICAL INFECTIOUS DISEASES

Echinocandin and Triazole Antifungal Susceptibility Profiles for Clinical Opportunistic Yeast and Mold Isolates Collected from 2010 to 2011: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values for Characterization of Geographic and Temporal Trends of Antifungal Resistance

(2013) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Optimizing Echinocandin Dosing and Susceptibility Breakpoint Determination viaIn VivoPharmacodynamic Evaluation against Candida glabrata with and withoutfksMutations

(2012) Alexander Lepak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Impact of Treatment Strategy on Outcomes in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials

(2012) D. R. Andes et al.   CLINICAL INFECTIOUS DISEASES

Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST)

(2012) M. A. Pfaller et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Frequency of Decreased Susceptibility and Resistance to Echinocandins among Fluconazole-Resistant Bloodstream Isolates of Candida glabrata

(2012) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Discovery of a Novel Class of Orally Active Antifungal β-1,3-d-Glucan Synthase Inhibitors

(2011) Scott S. Walker et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Use of Pharmacokinetic-Pharmacodynamic Analyses To Optimize Therapy with the Systemic Antifungal Micafungin for Invasive Candidiasis or Candidemia

(2011) David Andes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008–2009)

(2011) Michael A. Pfaller et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida Species

(2010) D. Andes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Epidemiology and Outcomes of Candidemia in 2019 Patients: Data from the Prospective Antifungal Therapy Alliance Registry

(2009) David L. Horn et al.   CLINICAL INFECTIOUS DISEASES

Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America

(2009) Peter G. Pappas et al.   CLINICAL INFECTIOUS DISEASES

Reduced Biocide Susceptibility in Candida albicans Biofilms

(2008) J. E. Nett et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Epidemiology of candidemia in intensive care units

(2008) Emilio Bouza et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS